Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$VDRM news!!
Last month we ran from .018 to .069 3 days after news! This news is much BIGGER!
http://www.marketwired.com/press-release/viaderma-receives-provisional-patent-numbers-its-fda-registered-viabecline-cannabis-otc-pink-vdrm-2203945.htm
March 20, 2017 08:00 ET
ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries
The Company will Target Countries where Medical and Recreational Cannabis Sales are Legal and Accepted and Scientific Research is Allowed
LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. "In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said Dr. Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."
"We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is aimed at the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.
CONTACT INFORMATION
Dr. Christopher Otiko
Chief Executive Officer
Email: info@viadermalicensing.com
Investor Relations Phone number: 310-734-6111
I agree! .10-12+ post conference!!
Long $VDRM
https://twitter.com/search?f=tweets&vertical=default&q=vdrm&src=typd
GAP UP in the AM!!
$VDRM
Thanks for posting Pistol Pete! Time for launch!!
$VDRM
So do I.. all these companies will want licensing agreements for the Cannabis Provisional Patent #62466209, a provisional patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution.
Think about it, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks over its closest competitor. If tests results are similar to Viabecline, for the MMJ space, do you think any other product on the planet will be able to compete with them?
We are talking $$'s when this happens, or a big buyout!
http://www.marketwired.com/press-release/viaderma-receives-provisional-patent-numbers-its-fda-registered-viabecline-cannabis-otc-pink-vdrm-2203945.htm
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Canopy Growth (TSX:WEED)
OrganiGram (TSXV:OGI)
THC Biomed Intl Ltd (CSNX:THC)
Maple Leaf Green World (TSXV:MGW)
Emerald Health Therapeutics (TSXV:EMH)
Tetra Bio-Pharma (CSNX:TBP)
PharmaCan Capital (TSXV:MJN)
Aphria (TSXV:APH)
Aurora Cannabis (CSNX:ACB)
Cannabix Technologies (CSNX:BLO)
Supreme Pharmaceuticals (CSNX:SL)
Mettrum Health (TSXV:MT)
MYM Nutraceuticals (CSE:MYM)
CannaRoyalty (CSE:CRZ)
Emblem (TSXV:EMC)
Liberty Leaf (CSE:LIB)
Valens GroWorks (CSE:VGW)
Marapharm Ventures (CSE:MDM)
Wildflower Marijuana (CSE:SUN)
True Leaf Pet (CSE:MJ)
Puf Ventures (CSE:PUF)
Cannabix (CSE:BLO)
Do you notice any BIG names that will be at the conference March 23-25, this week??
If you don't think ViaDerma won't have new $$ coming in during and post conference, then you shouldn't be investing here. I see .10-12+ post conference.
Sponsors
EDUCATIONAL GRANTS
This activity has been planned to be well-balanced, objective, and scientifically rigorous. Information and opinions offered by speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.
Texas Heart Institute, Office of Continuing Medical Education, along with Baylor College of Medicine, gratefully acknowledges the following companies for providing educational grant support for this activity
PLATINUM
Abbott Laboratories
BRONZE
Boston Scientific
Cardiovascular Systems, Inc.
Fashek Family Foundation
EXHIBITS, SYMPOSIA AND WORKSHOP SPONSORS
Support for this conference has been provided in part by the following exhibitor, symposium and workshop sponsors:
PLATINUM
Acelity
Abbott Vascular
BSN medical, Inc.
Integra LifeSciences
SILVER
Boston Scientific
Cook Medical
EO2 Concepts
W.L. Gore
MiMedx
NOVADAQ
Osiris Therapeutics
Tissue Regenix
Woundcare-Circle
BRONZE
Acell
Alliqua BioMedical
Anvil Orthotics
Arobella Medical LLC
Derma Sciences
Footbeat
Hanger Clinic
Herreen
Medela LLC
MedShape, Inc.
Misonix
MTF Wound Care
Organogenesis
Philips Volcano
Restorative Medical
RestorixHealth
Spectranetics
Siren Care
Stryker
FRIENDS OF DFCON
8th International Symposium on the Diabetic Foot
First Nations Limb Preservation Foundation
Wound Healing Society/Wound Healing Foundation
Inquires: dfcon@bcm.edu
News will leak tonight. It took 3 days after the last big PR for us to run. We then ran from .018 to .069
$VDRM
We will hit that and higher with the news spreading and the conference March 23-25
$VDRM
LOL... ok
$VDRM
News will spread tonight. GAP UP in the AM
$VDRM
Wrong!
https://www.drugs.com/otc/676986/viabecline.htm
Viabecline
Dosage form: ointment
Ingredients: TETRACYCLINE HYDROCHLORIDE 30mg in 1mL
Labeler: VIADERMA II, INC.
NDC Code: 69006-002
Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.
Viabecline Topical Ointment
Active Ingredient (in each gram)
Tetracycline Hydrochloride 30mg
Purpose
First Aid antibiotic
Use
First aid to help prevent skin infection in minor cuts, scrapes, and burns.
Warnings
For esternam use only. May be harmful is swallowed.
Allergy alert: Do not use if allergic to any ingredient listed on this label.
Do not use
In eyes
over large areas of the body
longer than 1 week unless directed by doctor
Ask a doctor before use if you have
?deep or puncture wounds
animal bites
serious trauma
Stop use and ask a doctor if condition persists or gets worse.
Keep our of reach of children. If swallowed, get medical help or contact a Poison control Center right away.
Directions
Clean the affected area
Apply a small amount of this product (an amount equal to the surface area of the tip of a finger) on the area 1 to 3 times daily.
May be covered with a sterile bandage.
Other Information
Keep product refrigerated to preserve its effectiveness and color
Stop use if product is misused
This product is an OTC antibiotic for human use
Contains no alcohol, no animal ingredients
Blended for typical skin color
May stain cloth
No claims regarding stem cell healing are implied for this product.
Inactive Ingredient
Acetic Acid, Ascorbic Acid, chlorhexidine gluconate, cholecalciferol, dimethyl sulfoxide, dipropylene glycol, glucono delta lactone, GLYCERIN, histidine, hydroxethylc-cellulose, magnesium stearate, methylparaben, sodium hydroxide, sorbic acid, steric acid, water.
Label- Viabecline Topical Ointment
VIABECLINE
tetracycline hydrochloride ointment
Product Information
Product Type HUMAN OTC DRUG Item Code (Source) NDC:69006-002
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
TETRACYCLINE HYDROCHLORIDE (TETRACYCLINE) TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL
Inactive Ingredients
Ingredient Name Strength
ACETIC ACID
ASCORBIC ACID
CHLORHEXIDINE GLUCONATE
CHOLECALCIFEROL
DIMETHYL SULFOXIDE
DIPROPYLENE GLYCOL
GLYCERIN
HISTIDINE
MAGNESIUM STEARATE
METHYLPARABEN
SODIUM HYDROXIDE
SORBIC ACID
WATER
Packaging
# Item Code Package Description
1 NDC:69006-002-00 1 BOTTLE in 1 BOX
1 5 mL in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
OTC monograph final part333B 11/08/2016
Labeler - VIADERMA II, INC. (079387584)
Registrant - VIADERMA II, INC. (079387584)
Revised: 11/2016
VIADERMA II, INC.
REPOST!
Why is no one talking about this?!? This is HUGE!!
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Canopy Growth (TSX:WEED)
OrganiGram (TSXV:OGI)
THC Biomed Intl Ltd (CSNX:THC)
Maple Leaf Green World (TSXV:MGW)
Emerald Health Therapeutics (TSXV:EMH)
Tetra Bio-Pharma (CSNX:TBP)
PharmaCan Capital (TSXV:MJN)
Aphria (TSXV:APH)
Aurora Cannabis (CSNX:ACB)
Cannabix Technologies (CSNX:BLO)
Supreme Pharmaceuticals (CSNX:SL)
Mettrum Health (TSXV:MT)
MYM Nutraceuticals (CSE:MYM)
CannaRoyalty (CSE:CRZ)
Emblem (TSXV:EMC)
Liberty Leaf (CSE:LIB)
Valens GroWorks (CSE:VGW)
Marapharm Ventures (CSE:MDM)
Wildflower Marijuana (CSE:SUN)
True Leaf Pet (CSE:MJ)
Puf Ventures (CSE:PUF)
Cannabix (CSE:BLO)
Why is no one talking about this?!? This is HUGE!!
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Canopy Growth (TSX:WEED)
OrganiGram (TSXV:OGI)
THC Biomed Intl Ltd (CSNX:THC)
Maple Leaf Green World (TSXV:MGW)
Emerald Health Therapeutics (TSXV:EMH)
Tetra Bio-Pharma (CSNX:TBP)
PharmaCan Capital (TSXV:MJN)
Aphria (TSXV:APH)
Aurora Cannabis (CSNX:ACB)
Cannabix Technologies (CSNX:BLO)
Supreme Pharmaceuticals (CSNX:SL)
Mettrum Health (TSXV:MT)
MYM Nutraceuticals (CSE:MYM)
CannaRoyalty (CSE:CRZ)
Emblem (TSXV:EMC)
Liberty Leaf (CSE:LIB)
Valens GroWorks (CSE:VGW)
Marapharm Ventures (CSE:MDM)
Wildflower Marijuana (CSE:SUN)
True Leaf Pet (CSE:MJ)
Puf Ventures (CSE:PUF)
Cannabix (CSE:BLO)
MODS pls sticky
$VDRM news!!
Last month we ran from .018 to .069 3 days after news! This news is much BIGGER!
March 20, 2017 08:00 ET
ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries
The Company will Target Countries where Medical and Recreational Cannabis Sales are Legal and Accepted and Scientific Research is Allowed
LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. "In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said Dr. Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."
"We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is aimed at the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.
CONTACT INFORMATION
Dr. Christopher Otiko
Chief Executive Officer
Email: info@viadermalicensing.com
Investor Relations Phone number: 310-734-6111
9:11 AM (38 minutes ago)
to Joanna
Hello,
I'd like to register for your event. How much is it for one day, on March 24?
Thank you
Starosolska, Joanna
9:29 AM (20 minutes ago)
to me
The one day rate is $275 for a doctor. The other rates are below. Registration for one day rates must be done on site.
MD/DO/DPM: $275 per day
Resident/Fellows: $90 per day
Nurse/PA/NP: $220 per day
Military: $140 per day
Industry: $275 per day
Companion/Guest: $70 per day
Regards,
Joanna Starosolska
Administrative Secretary
Division of Vascular Surgery
Baylor College of Medicine
One Baylor Plaza, MS 390
Houston, TX 77030
Ph: 713-798-7851
Fx: 713-798-2744
DFCon 2017
cid:image004.jpg@01D12770.3F6AF690
We ran two days after the last good PR
It will come
$VDRM
Dr Otiko has one year to file a regular non-provisional patent application.
Saaaaweet Jesus!! Wait till this news spreads via news feeds, twitter etc tonight.
Tuesday we will gap UP
$VDRM
Under United States patent law, a provisional application is a legal document filed in the United States Patent and Trademark Office (USPTO), that establishes an early filing date, but does not mature into an issued patent unless the applicant files a regular non-provisional patent application within one year.
The Cannabis Provisional Patent #62466209
The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications"
LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. "In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said Dr. Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."
Do investors even know how big ViaDerma's potential is??
I don't know of any other stock with this much potential!!!
Look back here in a year..
$VDRM
Totally agree. Company's can not make $$ without raising capital to do so!
$VDRM
Neptune, you wanted patent provisional #'s, now you have #'s!! LOL
No one cares about news from 4 years ago. Lets keep investors current
The Cannabis Provisional Patent #62466209
The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications"
LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. "In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said Dr. Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."
Conference will be BIG for ViaDerma!! March 23-25, this week..
Sponsors
EDUCATIONAL GRANTS
This activity has been planned to be well-balanced, objective, and scientifically rigorous. Information and opinions offered by speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.
Texas Heart Institute, Office of Continuing Medical Education, along with Baylor College of Medicine, gratefully acknowledges the following companies for providing educational grant support for this activity
PLATINUM
Abbott Laboratories
BRONZE
Boston Scientific
Cardiovascular Systems, Inc.
Fashek Family Foundation
EXHIBITS, SYMPOSIA AND WORKSHOP SPONSORS
Support for this conference has been provided in part by the following exhibitor, symposium and workshop sponsors:
PLATINUM
Acelity
Abbott Vascular
BSN medical, Inc.
Integra LifeSciences
SILVER
Boston Scientific
Cook Medical
EO2 Concepts
W.L. Gore
MiMedx
NOVADAQ
Osiris Therapeutics
Tissue Regenix
Woundcare-Circle
BRONZE
Acell
Alliqua BioMedical
Anvil Orthotics
Arobella Medical LLC
Derma Sciences
Footbeat
Hanger Clinic
Herreen
Medela LLC
MedShape, Inc.
Misonix
MTF Wound Care
Organogenesis
Philips Volcano
Restorative Medical
RestorixHealth
Spectranetics
Siren Care
Stryker
FRIENDS OF DFCON
8th International Symposium on the Diabetic Foot
First Nations Limb Preservation Foundation
Wound Healing Society/Wound Healing Foundation
Inquires: dfcon@bcm.edu
http://dfcon.com
Contact
1 Baylor Plaza, Houston, TX
+1 832 355 9100
dfcon@bcm.edu
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 23-25, 2017 ~
http://www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
http://dfcon.com
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129403043
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129390203
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129368069
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129334996
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129312100
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129311752
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129297007
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129296364
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129295215
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129286262
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129196331
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129040891
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128962099
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128961948
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128957163
https://twitter.com/search?f=tweets&vertical=default&q=vdrm&src=typd
2's will soon be a thing of the past, so will 3's & 4's
$VDRM
Here you go again LOL
Neptune, you wanted patent #'s, now you have #'s!! LOL
The Cannabis Provisional Patent #62466209
The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications"
LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. "In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said Dr. Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."
Neptune, you wanted patent #'s, now you have #'s!! LOL
The Cannabis Provisional Patent #62466209
The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications"
LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. "In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said Dr. Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."
It's a biotech pharma play and a MMJ play!
Start of a MASSIVE run! We will break new highs this month.
Hang on for the ride
$VDRM
Us LONGS do! Last time a good news release came out on February 15th, and we didn't start running until 2 days later on February 17th. We ran from .018 to .069
This news release is better than anything we have had released to date!
PLUS DOCS from all over the world will hear about ViaDerma this week!
Starosolska, Joanna <Joanna.Starosolska@bcm.edu>
9:39 AM Wednesday, March 15, 2017
to me
Good morning,
Dr. Otiko has been invited to present his poster during the poster session at DFCon. This is a formal session, but it is not an exclusive speaking event.
Poster session will take place on March 24 from 11:40 am to 2:20 pm.
With kind regards,
Joanna Starosolska
Administrative Secretary
Division of Vascular Surgery
Baylor College of Medicine
One Baylor Plaza, MS 390
Houston, TX 77030
Ph: 713-798-7851
Fx: 713-798-2744
DFCon 2017
cid:image004.jpg@01D12770.3F6AF690
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
http://dfcon.com
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
February 8, 2017
~ CEO speaking at the Global Diabetic Foot Conference in Houston March 23-25, 2017 ~
http://www.marketwired.com/press-release/dr-chris-ayo-otiko-president-viaderma-inc-is-selected-write-article-healing-diabetic-otc-pink-vdrm-2194656.htm
https://www.drugs.com/otc/676986/viabecline.html
https://www.linkedin.com/pulse/healing-diabetic-ulcers-dave-pozek-1
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129403043
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129390203
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128962099
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
February 3, 2017
~ MASSIVE sales coming.. 500,000 units x $125 = $62,500,000 in 2017~
http://www.marketwired.com/press-release/viaderma-inc-targets-online-sales-wound-care-centers-distribution-companies-its-viabecline-pinksheets-vdrm-2193323.htm
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129402236
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129339194
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129286070
Nice work Cheds! Going to be a fun few weeks coming up!
$VDRM
Wait until it spreads, especially into the MMJ sector! News just came out 2 hours ago
$VDRM
Long Fire, welcome to the VDRM gang! Going to be a fun few weeks ahead!
$VDRM
Stocks2727, welcome to the VDRM gang! Going to be a fun few weeks ahead!
$VDRM
$VDRM news!!
Last month we ran from .018 to .069 3 days after news! This news is 10x's BIGGER!
March 20, 2017 08:00 ET
ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries
The Company will Target Countries where Medical and Recreational Cannabis Sales are Legal and Accepted and Scientific Research is Allowed
LOS ANGELES, CA--(Marketwired - March 20, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has received the Provisional Patent number for two patents pending. The Cannabis Provisional Patent #62466209, a patent for delivering medical marijuana /cannabis to the body by applying the medication onto the skin in an ointment base topical solution. The second provisional patent #62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2017.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Company CEO Dr. Christopher Otiko is attending the Diabetic Foot Global Conference (DFCon 20017), at Baylor College of Medicine in Houston, Texas and on Friday 24th of March will present a poster abstract based on seven years of research treating patients with Viabecline. "In recent studies, Viabecline has been more than 96% effective in healing diabetic foot ulcers within 4 weeks. This effect is more pronounced in more severe wounds, and the effect is the same whether the wound is infected or not," said Dr. Otiko. "Our goal is to have Viabecline added to all diabetic foot ulcer treatment protocols."
"We are also continuing the clinical testing stages of an anti-aging topical solution, a topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido. The market for our many products is very promising. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Otiko.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD and THC with the delivery system was filed in 2017. The use of CBD is aimed at the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com
Forward Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.
CONTACT INFORMATION
Dr. Christopher Otiko
Chief Executive Officer
Email: info@viadermalicensing.com
Investor Relations Phone number: 310-734-6111
I've been calling .10-12+ for the past 6 weeks!
It'll come. Last time we ran to .069 3 days after the last PR regarding patents, now we have patent #'s, conference in 3 days, and a LOI signed!!!!
That is MASSIVE news
"The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries."
$VDRM
Very little on the ASK, .035 will be here within an hour!! Then we run from there!
That release is the BIGGEST one yet!!
HUGE week ahead!!
$VDRM